Table 2 The ongoing clinical trials with MSCs interventions in COVID-19 patients

NCT04461925

Recruiting

Phase 1

Phase 2

Severe

Interventional

hU-MSCs

Allogenic

IV

3

1.0*10e6/kg

30

Ukraine

Non-randomized

Controlled

NCT04452097

Not yet recruiting

Phase 1

Phase 2

Severe

Interventional

hU-MSCs (BX-U001)

Allogenic

IV

1 (either one from the 3)

0.5*10e6, 1.0*10e6, or 1.5 × 10e6 cells/kg

39

N/A

Non-randomized

Uncontrolled

NCT04377334

Not yet recruiting

Phase 2

Interventional

BM-MSCs

Allogenic

N/A

N/A

40

Germany

Randomized

Controlled

NCT04331613

Recruiting

Phase 1

Phase 2

Severe

Interventional

hESCs-derived-IMRCs (CAstem)

Allogenic

IV

1–3 Doses

3*10e6, 5*10e6, or 10*10e6 cells/kg

9

China

N/A

Uncontrolled

NCT04390139

Recruiting

Phase 1

Phase 2

Moderate

Interventional

WJ-MSCs

N/A

Endovenous

2

1*10e6 cells/kg

30

Spain

Randomized

Controlled

NCT04371393

Recruiting

Phase 3

Moderate to severe

Interventional

BM-MSCs (Remestemcel-L)

Allogenic

IV

2

2*10e6 cells/kg

300

United States

Randomized

Controlled

NCT04348461

Not yet recruiting

Phase 2

Severe (on Mechanical ventilation)

Interventional

AT-MSCs

Allogenic

IV

2

1.5*10e6 cells/kg

100

Ukraine

Randomized

Controlled

NCT04400032

Recruiting

Phase 1

Severe (on Mechanical ventilation ≤ 48 h)

Interventional

BM-MSCs

N/A

IV

3

25*10e6, 50*10e6, or 90*10e6 cells

9

Canada

Non-randomized

Uncontrolled

NCT04398303

Not yet recruiting

Phase 1

Phase 2

Moderate to severe

Interventional

hU-MSCs (ACT-20), ACT-20-CM or hU-MSCs in CM (ACT-20)

Allogenic

IV

N/A

1*10e6 cells/kg of hU-MSCs (ACT-20) in 100 ml CM, 100 ml CM of ACT-20-CM

70

N/A

Randomized

Controlled

NCT04393415

Recruiting

Not applicable

Any

Interventional

hU-MSCs

N/A

N/A

N/A

N/A

100

Egypt

Randomized

Controlled

NCT04447833

Recruiting

Phase 1

Severe

Interventional

BM-MSCs (KI-MSC-PL-205)

Allogenic

IV

1

1*10e6 or 2*10e6 cells/kg

9

Sweden

N/A

Uncontrolled

NCT04397796

Recruiting

Phase 1

Moderate to severe

Interventional

BM-MSCs

Allogenic

N/A

N/A

N/A

45

United States

Randomized

Controlled

NCT04467047

Not yet recruiting

Phase 1

Severe

Interventional

BM-MSCs

Allogenic

IV

N/A

1*10e6 cells/kg

10

N/A

N/A

Uncontrolled

NCT03042143

Recruiting

Phase 1

Phase 2

Moderate to severe

Interventional

hU-MSCs (Orbcel-C)

Allogenic

IV

N/A

400*10e6 cells

75

United Kingdom

Randomized

Controlled

NCT04345601

Not yet recruiting

Early Phase 1

Moderate to severe

Interventional

MSCs

Allogenic

IV

1

2*10e6 cells/kg

30

United States

Randomized

Controlled

NCT04269525

Recruiting

Phase 2

Severe or critical

Interventional

hU-MSCs

N/A

IV

4

9.9*10e7 cells

16

China

N/A

Uncontrolled

NCT04365101

Recruiting

Phase 1

Phase 2

Moderate

Interventional

hP-MSCs (CYNK-001)

Allogenic

IV

3

N/A

86

United States

Randomized

Controlled

NCT04361942

Recruiting

Phase 2

Severe

Interventional

MSCs

Allogenic

IV

1

10e6 cells/kg

24

Spain

Randomized

Controlled

NCT04389450

Recruiting

Phase2

Severe

Interventional

hP-MSCs (PLX-PAD)

Allogenic

IM

1 or 2

N/A

140

United States

Randomized

Controlled

NCT04333368

Active, not recruiting

Phase 1

Phase 2

Severe

Interventional

WJ-MSCs

IV (either centrally or peripherally)

3

10e6 cells/kg

47

France

Randomized

Controlled

NCT04367077

Recruiting

Phase 2

Phase 3

Moderate to severe

Interventional

BM-MSCs (MultiStem)

Allogenic

IV

N/A

N/A

400

United States

Randomized

Controlled

NCT04445220

Recruiting

Phase 1

Phase 2

Any

Interventional

Extracorporeal MSCs (SBI-101)

Allogenic

IV

1

250*10e6 or 750*10e6 cells

22

N/A

Randomized

Controlled

NCT04466098

Recruiting

Phase 2

Moderate to severe

Interventional

MSCs

N/A

IV

3

300*10e6 cells

30

United States

Randomized

Controlled

NCT04276987

Completed

Phase 1

Severe

Interventional

AT-MSCs -Exo

Allogenic

Inhalation

5

2*10e8 nanovesicles/3 ml

24

China

N/A

Uncontrolled

NCT04313322

Recruiting

Phase 1

Interventional

WJ-MSCs

Allogenic

IV

3

1*10e6 cells/kg

5

Jordan

N/A

Uncontrolled

NCT04473170

Completed

Phase 1 and Phase 2

Interventional

Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)

Autologous

jet nebulization

N/A

N/A

146

United Arab Emirates

Randomized

Controlled

NCT04428801

Not yet recruiting

Phase 2

Interventional

AT-MSCs

Autologous

IV

3

200*10e6 cells

200

N/A

Randomized

Controlled

NCT04486001

Not yet recruiting

Phase 1

Severe

Interventional

AT-MSCs

Allogenic

IV

20

United States

N/A

Uncontrolled

NCT04444271

Recruiting

Phase 2

Moderate

Interventional

MSCs

N/A

IV

1 or 2

2*10e6 cells/kg

20

Pakistan

Randomized

Controlled

NCT04416139

Recruiting

Phase 2

Severe

Interventional

MSCs

Allogenic

IV

1

1*10e6 cells/kg

10

Mexico

Non-randomized

Controlled

NCT04336254

Recruiting

Phase 1

Phase 2

Severe

Interventional

DPSCs

Allogenic

IV

3

3.0*10e7 cells

20

China

Randomized

Controlled

NCT04429763

Not yet recruiting

Phase 2

Severe

Interventional

hU-MSCs

N/A

N/A

1

1*10e6 cells/Kg

30

United States

Randomized

Controlled

NCT04315987

Not yet recruiting

Phase 2

Severe

Interventional

MSCs (NestaCell®)

allogenic

IV

4

2*10e7 cells

90

Brazil

Randomized

Controlled

NCT04456361

Active, not recruiting

Early Phase 1

Mild–moderate–severe

Interventional

WJ-MSCs

N/A

IV

1

1*10e8 cells

9

Mexico

N/A

Uncontrolled

NCT04349631

Active, not recruiting

Phase 2

N/A

Interventional

AT-MSCs

Autologous

IV

5

N/A

56

United States

N/A

Uncontrolled

NCT04366323

Active, not recruiting

Phase 1

Phase 2

severe

Interventional

AT-MSCs

Allogeneic

IV

2

80*10e6 cells

26

Spain

Randomized

Controlled

NCT04348435

Enrolling by invitation

Phase 2

Interventional

AT-MSCs (Hope Biosciences-MSCs)

Allogeneic

IV

5

200*10e6 cells

100

United States

Randomized

Controlled

NCT04252118

Recruiting

Phase 1

Interventional

MSCs

N/A

IV

3

3*10e7 cells

20

China

Non-RANDOMIZED

Controlled

NCT04273646

Not yet recruiting

Not applicable

Severe

Interventional

hU-MSCs

N/A

IV

4

0.5*10e6 cells/kg

48

China

Randomized

Controlled

NCT04382547

Enrolling by invitation

Phase 1

Phase 2

Severe

Interventional

OM-MSCs

Allogeneic

IV

N/A

N/A

40

Belarus

Non-randomized

Controlled

NCT04346368

Not yet recruiting

Phase 1

Phase 2

Severe

Interventional

BM-MSCs

N/A

IV

1

1*10e6 cells/kg

20

China

Randomized

Controlled

NCT04288102

Completed

Phase 2

Severe

Interventional

hU-MSCs

IV

3

4.0*10e7 cells

100

China

Randomized

Controlled

NCT04527224

Not yet recruiting

Phase 1

Phase 2

Moderate

Interventional

AT-MSCs (AstroStem-V)

Allogenic

N/A

N/A

N/A

10

N/A

Uncontrolled

NCT04339660

Recruiting

Phase 1

Phase 2

Interventional

hU-MSCs

N/A

IV

1

1*10e6 cells/kg

30

China

Randomized

Controlled

NCT04457609

Recruiting

Phase 1

Severe

Interventional

hU-MSCs

N/A

IV

1

1*10e6 cells/kg

40

Indonesia

Randomized

Controlled

NCT04366063

Recruiting

Phase 2

Phase 3

Mild to moderate

Interventional

MSCs

N/A

IV

2

100*10e6 (± 10%) cells

60

Islamic Republic of Iran

Randomized

Controlled

NCT04490486

Not yet recruiting

Phase 1

Interventional

hU-MSCs

N/A

IV

2

100*10e6 cells

21

United States

Randomized

Controlled

NCT04355728

Completed

Phase 1

Phase 2

Severe

Interventional

hU-MSCs

IV

2

100*10e6 cells

24

United States

Randomized

Controlled

NCT04535856

Recruiting

Phase 1

Mild or moderate

Interventional

DW-MSC

allogeneic

IV

2

Low-dose group (5*10e7 cells)

High-dose group (1*10e8 cells)

9

Indonesia

Randomized

Controlled

NCT04537351

Recruiting

Phase 1

Phase 2

Interventional

iPSCs-derived-MSCs (Cymerus MSCs)

Allogenic

IV

2

2–200*10e6 cells/kg

24

Australia

Randomized

Controlled

NCT04524962

Recruiting

Phase 1

Phase 2

Moderate-to-severe

Interventional

RNA-engineered MSCs to secrete DNases

N/A

N/A

N/A

30

United States

N/A

Uncontrolled

NCT04371601

Active, not recruiting

Early Phase 1

Severe

Interventional

hU- MSCs

IV

4

10e6 cells/Kg

60

China

Randomized

Controlled

NCT04522986

Not yet recruiting

Phase 1

Severe

Interventional

MSCs

IV

4

1*10e8 cells

6

Japan

N/A

Uncontrolled

NCT04362189

Active, not recruiting

Phase 2

Interventional

AT-MSCs (Hope Biosciences-MSCs)

Allogeneic

IV

4

100*10e6 cells

100

United States

Randomized

Controlled

NCT04390152

Not yet recruiting

Phase 1

Phase 2

Moderate to severe

Interventional

WJ-MSCs

N/A

IV

2

50*10e6 cells

40

Colombia

Randomized

Controlled

NCT04611256

Recruiting

Phase 1

Moderate to severe

Interventional

AT-MSCs

N/A

IV

2

1*10e6 cells/kg

20

Mexico

Randomized

Controlled

NCT04565665

Recruiting

Phase 1

Moderate to severe

Interventional

hU-MSCs

IV

1 or 2

N/A

70

United States

Randomized

Controlled

NCT04573270

Completed

Phase 1

N/A

Interventional

MSCs

N/A

IV

1

N/A

40

United States

Randomized

Controlled

NCT04629105

Recruiting

Phase 1

Mild to severe

Interventional

BM-MSCs (Longeveron MSCs)

IV

3

100*10e6 cells

70

United States

Randomized

Controlled

NCT04302519

Not yet recruiting

Early Phase 1

Severe

Interventional

DP-MSCs

N/A

IV

3

1.0*10e6 cells/kg

24

China

Randomized

Uncontrolled

NCT04494386

Recruiting

Phase 1

Phase 2

Mild–moderate–severe

Interventional

hU-MSCs

Allogeneic

IV

1 or 2

100*10e6 cells

60

United States

Randomized

Controlled

NCT04392778

Recruiting

Phase 1

Phase 3

Severe

Interventional

MSCs

N/A

IV

3

3*10e6 cells/kg

30

Turkey

Randomized

Controlled

NCT04657458

Available

Severe

Expanded access

BM-MSC -Derived-ECV(ExoFlo™)

N/A

IV

N/A

N/A

N/A

N/A

N/A

NCT04299152

Not yet recruiting

Phase 2

Interventional

hU-MSCs (stem cell educator therapy)

IV

1

N/A

20

Randomized

Controlled

NCT04625738

Not yet recruiting

Phase 2

Moderate to severe

Interventional

WJ-MSCs

IV

3

1*10e6 cells/kg, 0.5*10e6 and 0.5*10e6

30

France

Randomized

Controlled

NCT04492501

Completed

Not applicable

Moderate and severe

Interventional

MSCs either alone or in combination with other novel therapies

IV

1

2*106 cells/kg

600

Pakistan

Non-randomized

Controlled